Sanofi wins EU green light for new MS drug Lemtrada
LONDON, June 28
LONDON, June 28 (Reuters) - French firm Sanofi has won a European green light for its new multiple sclerosis medicine Lemtrada, after a quarter-century drug development saga.
Lemtrada, also known as alemtuzumab, has been studied in multiple sclerosis (MS) since the early 1990s but its progress to market as a treatment for the disease has been halting and the drug has changed hands many times.
The European Medicines Agency said on Friday it was recommending Lemtrada for relapsing-remitting MS. EMA decisions are usually endorsed by the European Commission within a couple of months. (Reporting by Rosalba O'Brien and Caroline Copley)
- U.S. war veteran released by North Korea returns home |
- South Korea to make announcement on air zone; expansion is anticipated |
- South Korea expands air defense zone to partially overlap China's |
- Pro-Europe protesters gather for rally in Kiev
- Pennsylvania newlyweds "just wanted to murder someone together:" police